Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 6/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19848442 | 0.91 | SLC9A1 (0.57) | SLC9A1HCAR3GLATSHRCYP11B2 | |
| SCHEMBL19915945 | 0.88 | HCAR3 (0.56) | SLC9A1HCAR3GLATSHRCYP17A1 | |
| SCHEMBL6187558 | 0.88 | SLC9A1 (0.53) | SLC9A1HCAR3GLATSHRCYP11B2 | |
| SCHEMBL19915673 | 0.82 | SLC9A1 (0.46) | SLC9A1HCAR3GLATSHR | |
| SCHEMBL17103014 | 0.82 | GLA (0.40) | SLC9A1GLATSHRCYP11B2CYP11B1 | |
| SCHEMBL19848164 | 0.81 | SLC9A1 (0.45) | SLC9A1HCAR3 | |
| SCHEMBL19848267 | 0.81 | TSHR (0.43) | SLC9A1GLATSHRCYP11B2CYP11B1 | |
| SCHEMBL17103041 | 0.81 | SLC9A1 (0.52) | SLC9A1HCAR3GLATSHRCYP11B2 | |
| SCHEMBL19848264 | 0.81 | CYP11B2 (0.41) | SLC9A1HCAR3GLATSHRCYP11B2 | |
| SCHEMBL29342227 | 0.81 | MAPT (0.44) | SLC9A1GLATSHRCYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885HCAR3 4636/4885GLA 4099/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885HCAR3 4636/4885GLA 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.